BPN 14770

Drug Profile

BPN 14770

Alternative Names: BPN-14770

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tetra Discovery Partners
  • Class Antidementias; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Cognition disorders

Highest Development Phases

  • Phase II Fragile X syndrome
  • Phase I Alzheimer's disease

Most Recent Events

  • 25 Jun 2018 Phase-II clinical trials in Fragile X syndrome in USA (unspecified route) after June 2018 (NCT03569631)
  • 03 Apr 2018 BPN 14770 receives Orphan Drug status for Fragile X syndrome in USA
  • 15 Mar 2018 Tetra Discovery Partners plans a phase II trial for Fragile X Syndrome (In adults) in USA in Q2 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top